Does SelectHealth Cover Prolia?

What Is Prolia and Why Does Coverage Matter?

Prolia is the brand name for denosumab, a RANK-ligand inhibitor that reduces osteoclast-mediated bone resorption. The FDA approved it in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and later expanded labeling covers men with osteoporosis, patients on long-term glucocorticoids, and patients receiving androgen-deprivation or aromatase-inhibitor therapy [1]. Because it is a biologic administered by injection, it lands in a specialty drug tier on most formularies, and list prices near $1,900 per dose make insurer approval financially significant for most patients.

How Prolia Works

Denosumab binds to RANK-L, the signaling protein that activates bone-resorbing osteoclasts. By blocking that signal, it slows bone breakdown without incorporating permanently into the bone matrix the way bisphosphonates do. The FREEDOM trial (N=7,808) showed that denosumab reduced the risk of new vertebral fractures by 68% at 3 years compared with placebo (P<0.001) [2]. That fracture-reduction profile is why prescribers often choose it over oral agents for patients with gastrointestinal intolerance or poor oral-bisphosphonate adherence.

Why Insurance Scrutiny Is Intense

Biologics command high acquisition costs, so payers including SelectHealth apply utilization management tools such as prior authorization, step therapy, and quantity limits. The American Association of Clinical Endocrinology 2020 guidelines state: "Pharmacological therapy is recommended for patients with osteoporosis who are at high risk for fracture, using agents proven to reduce vertebral and nonvertebral fractures" [3]. Insurance reviewers use criteria drawn from such guidelines to decide whether Prolia is medically necessary for a specific patient.

SelectHealth Plan Types and How They Handle Prolia

SelectHealth is a Utah-based health plan affiliated with Intermountain Health. It sells employer-sponsored commercial plans, individual and family marketplace plans, Medicaid managed care (SelectHealth Community Care), and Medicare Advantage (SelectHealth Advantage). Coverage rules differ meaningfully across these product lines.

Commercial and Marketplace Plans

On SelectHealth commercial formularies, denosumab typically sits at Tier 3 or Tier 4 (specialty). Prior authorization is required for virtually every covered member. Step-therapy protocols usually demand documented use of an oral bisphosphonate for at least 3 to 6 months unless the patient has a documented contraindication or intolerance. Supporting documentation generally must include a DEXA scan result showing a T-score of <-2.5 or a prior fragility fracture.

Medicare Advantage (SelectHealth Advantage)

Under Medicare Part B, Prolia administered in a physician office is covered as a medical benefit rather than a pharmacy benefit because it is a provider-administered injectable. SelectHealth Advantage plans mirror traditional Medicare Part B cost-sharing, so the patient typically pays 20% of the Medicare-approved amount after the Part B deductible ($257 in 2025) is met [4]. Prior authorization still applies on most SelectHealth Advantage plans, but step-therapy restrictions are often less stringent for Medicare enrollees given CMS guidance limiting step therapy for Part B drugs.

Medicaid Managed Care (SelectHealth Community Care)

Utah Medicaid covers Prolia for qualifying members, but coverage criteria follow state preferred drug list rules. The Utah Medicaid preferred drug list generally requires prior authorization and clinical justification. Income-qualified patients on SelectHealth Community Care may have minimal or zero cost-sharing once prior authorization is approved.

Prior Authorization: What SelectHealth Requires

Prior authorization (PA) for Prolia on SelectHealth commercial plans typically requires the following elements. Missing any one of them is the most common reason for initial denial.

Diagnosis and BMD Documentation

The prescribing clinician must document an ICD-10-CM code consistent with osteoporosis (e.g., M81.0 for age-related osteoporosis without current pathological fracture) or a fragility fracture code. A DEXA scan report showing a T-score of <-2.5 at the lumbar spine, femoral neck, or total hip satisfies the BMD criterion on most SelectHealth PA forms. Patients with a prior fragility fracture and a T-score between -1.0 and -2.5 (osteopenia range) may still qualify if fracture risk calculated by FRAX exceeds plan-defined thresholds.

Step Therapy and Bisphosphonate Trial

Most SelectHealth commercial plans require documented failure, intolerance, or contraindication to an oral bisphosphonate before Prolia is approved. Alendronate 70 mg weekly (generic, approximately $10 per month) is the usual first-line agent referenced. Acceptable reasons to bypass this requirement include:

• Esophageal motility disorders or active esophageal disease
• Inability to remain upright for 30 minutes post-dose
• Renal impairment with creatinine clearance <35 mL/min (per FDA labeling, bisphosphonates are generally avoided at this threshold) [5]
• Prior jaw osteonecrosis or atypical femur fracture attributable to a bisphosphonate

Quantity Limits

Prolia is approved as one 60 mg injection every 6 months. SelectHealth quantity limits reflect this exactly: one unit per 180 days. Claims submitted outside that window are denied at the pharmacy or provider billing level automatically.

What You Will Pay: Out-of-Pocket Cost Scenarios

The final patient cost depends on the plan's benefit design, whether Prolia is obtained through a specialty pharmacy benefit or a medical benefit, and whether the patient uses available manufacturer assistance.

Specialty Pharmacy Benefit (Commercial Plans)

When billed through the pharmacy benefit, Prolia typically falls in the specialty tier. Coinsurance on specialty drugs commonly runs 20% to 33% on SelectHealth commercial plans. At a negotiated price of roughly $1,600 per dose, 20% coinsurance equals $320 per injection or $640 per year before any out-of-pocket maximum credit. Once the annual out-of-pocket maximum is reached, the plan pays 100%.

Medical Benefit (Office-Administered)

When Prolia is administered in a physician office and billed as a medical claim, cost-sharing follows the plan's specialist visit or procedure coinsurance rules. This is frequently more favorable than the specialty pharmacy tier, which is why many endocrinologists and rheumatologists prefer to administer Prolia in-office and bill under the medical benefit.

Amgen Prolia Copay Assistance

Amgen operates a copay assistance program for commercially insured patients. Eligible patients with commercial coverage (not Medicare or Medicaid) may pay as little as $0 per dose, with the program covering up to $3,600 per year [6]. Patients can enroll at Amgen's patient support website; the prescribing office can also enroll patients directly.

Amgen Assistance for Uninsured or Underinsured Patients

Amgen's Assist program provides Prolia at no charge to patients who are uninsured or underinsured and meet income eligibility criteria. Income thresholds are updated annually; the program's existence means even patients without SelectHealth approval have a potential pathway to the medication.

How to Get SelectHealth to Approve Prolia: Step-by-Step

Getting a PA approved on the first submission saves weeks of delay. The following sequence reflects what HealthRX clinical coordinators have found most effective when supporting Prolia authorization requests.

Step 1: Confirm the Correct Coverage Pathway

Before submitting a PA, determine whether the claim will route through the pharmacy benefit or the medical benefit. Call SelectHealth member services (the number is on the back of the insurance card) and ask specifically: "Is denosumab covered under the pharmacy benefit or the medical benefit on this plan?" The answer shapes which PA form to submit and which department reviews it.

Step 2: Gather All Required Clinical Documents

Assemble the following before the PA is submitted:

• Most recent DEXA scan report (within 24 months is preferred; SelectHealth may accept older scans with clinical justification)
• ICD-10 diagnosis codes
• Documentation of step-therapy trial or written rationale for bypass
• FRAX score if T-score is in the osteopenia range
• Prescriber's clinical notes supporting high fracture risk

Step 3: Submit the PA Through the Correct Channel

SelectHealth accepts PA submissions via phone, fax, and the Availity provider portal. Electronic submission through Availity typically generates a faster decision (often 3 to 5 business days for non-urgent cases). Urgent or expedited reviews must be completed within 72 hours under most state and federal rules [7].

Step 4: Track the PA and Follow Up

After submission, call SelectHealth's utilization management line at 48 hours to confirm receipt. Note the PA reference number. If no decision arrives within the standard turnaround, escalate to the plan's peer-to-peer review line; many denials reverse at this stage when the prescribing physician speaks directly with the reviewing medical director.

What To Do If SelectHealth Denies Prolia Coverage

Denial is not the end of the road. Federal law (under the Affordable Care Act and ERISA for employer plans) guarantees internal and external appeal rights [8].

Internal Appeal

File a written internal appeal within the plan's stated deadline, typically 60 to 180 days from the denial notice. The appeal packet should include:

• A letter of medical necessity from the prescriber citing the FREEDOM trial data (68% vertebral fracture reduction) [2] and the patient's specific fracture risk factors
• Published clinical guidelines, such as the 2020 AACE/ACE Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis, which support Prolia as a first-line option for patients at very high fracture risk [3]
• Any peer-reviewed literature supporting Prolia use in the patient's specific situation

Peer-to-Peer Review

Request a peer-to-peer call between the patient's prescriber and SelectHealth's reviewing physician. Studies of managed care PA processes suggest that peer-to-peer calls reverse 30% to 50% of initial denials in specialty drug categories [9]. Schedule this call quickly; most plans allow it only before or during the internal appeal window.

External Appeal

If the internal appeal is denied, the patient has the right to an independent external review by a state-certified organization. Utah requires health plans to offer external review under Utah Code 31A-22-629. The external reviewer's decision is binding on the insurer [8].

State Insurance Commissioner Complaint

Filing a complaint with the Utah Insurance Department is free and creates a formal record. Regulators track denial patterns and may contact the plan on the patient's behalf, which sometimes accelerates resolution.

Clinical Evidence Supporting Prolia Use: What the Literature Shows

Insurance reviewers assess medical necessity against published evidence. Understanding that evidence helps prescribers write more persuasive PA letters.

Fracture Reduction Data

The FREEDOM trial (N=7,808, 3 years) demonstrated denosumab reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% versus placebo (all P<0.001) [2]. The FREEDOM Extension study followed participants for up to 10 years and showed continued fracture risk reduction with sustained BMD gains at the lumbar spine and total hip [10].

Comparison with Bisphosphonates

Head-to-head data favor denosumab for BMD gains. The DECIDE trial (N=1,189) found denosumab produced significantly greater BMD increases at the total hip compared with alendronate at 12 months (3.5% vs. 2.6%, P<0.0001) [11]. For PA reviewers applying step-therapy criteria, a prescriber can reference this difference to argue that denosumab offers clinically meaningful benefit beyond what the oral agent achieved.

Guideline Endorsement

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women lists denosumab as a recommended pharmacotherapy alongside bisphosphonates, stating: "We suggest using denosumab as an alternative first-line treatment in postmenopausal women with osteoporosis" [12]. That "first-line" language is meaningful when arguing against mandatory step therapy.

Special Populations: Glucocorticoid-Induced Osteoporosis and Oncology Indications

Prolia carries separate FDA approvals for patients on long-term glucocorticoid therapy and for patients undergoing androgen-deprivation therapy (ADT) for prostate cancer or aromatase-inhibitor therapy for breast cancer [1]. SelectHealth PA criteria for these indications differ from postmenopausal osteoporosis criteria. Step-therapy requirements are often waived when the indication is ADT-associated bone loss, because guidelines recommend bone-protective therapy earlier in that population. Prescribers should submit PA requests referencing the specific FDA-approved indication to ensure the reviewer applies the correct clinical criteria.

Frequently Asked Questions